Share Name Share Symbol Market Type Share ISIN Share Description
Reliance Gen. LSE:GMX London Ordinary Share GB00B1MM9925 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.55p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.5 -2.5 -0.9 - 0.86

Reliance Genemedix Share Discussion Threads

Showing 601 to 615 of 625 messages
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
DateSubjectAuthorDiscuss
03/2/2010
20:03
whats happened here?normally there would be rampers all over a rise like this. seems to of gone unnoticed....
olly2
03/2/2010
14:35
vertical, perhaps due to the warrant conversion at 12.5p, although that gives tha majority shareholder 79%..... saffy..
safman
10/4/2008
10:19
Anyone know the latest on this?
undertaker
21/6/2007
16:10
40,000 shares bought or sold today.
barbra2
01/6/2007
10:12
has this really got 9 mill cash yet mcap below that.
powwow
07/2/2007
16:37
Don't know enough about the company wiganer. You shorting it? Good Wigan URL http://www.shof.msrcsites.co.uk/wigan.jpg :)
volsung
07/2/2007
16:32
Looks a cracking short for anyone who goes in for that kind of thing vols. Compare the current price with the placing price.
wiganer
07/2/2007
16:30
Dis has did well good today.
volsung
25/7/2006
12:31
Why is this company cap'd @£14million, is it april 1st, on my calc the share price should be 1/2p...any thoughts?
jotoha1
17/1/2006
19:50
Full time results Friday. share price will add a bit I believe but a safe holding to offset CGT.
eriktherock
23/11/2005
19:50
I only hold to offset CGT. lol. 30p soon
eriktherock
11/11/2005
19:18
Post removed by ADVFN
Abuse team
13/10/2005
11:09
ENCOURAGING STUFF! RNS Number:6088S GeneMedix PLC 13 October 2005 FOR IMMEDIATE RELEASE 13 October 2005 GENEMEDIX PLC Sale of Chinese Facility, Convertible Loan Funding GeneMedix plc ("GeneMedix" or "the Company"), the UK biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, announces that, as part of its recently announced restructuring, it has signed a binding letter of intent for the sale of its Chinese facility and has entered into a related party transaction to bring in additional financing to the business. The £500,000 financing will contribute to the Company's immediate funding requirements, and the sale of the Chinese facility, after payment of all debt, will provide approximately £1.6 million in early 2006. If the Company is to continue to pursue it EPO programme at its current rate, additional financing will be required over the coming months. The Board of Directors plans to access this additional funding from the restructuring process. The Chinese facility has not been part of the Company's core activities for some time and the funding of the sale will occur upon receipt of Chinese government approval. In the financing, GeneMedix placed a convertible loan of £500,000 with its founder and Chairman, Dr Kim Tan. These loan notes are convertible into between 11.8 and 13.1 million shares of the Company's shares when the Company completes its next share offering. To facilitate the financing of this convertible loan, a trust holding certain of Dr Kim Tan's shares in GeneMedix disposed of 18,567,397 GeneMedix shares at a price of 2.8p in a private placing with a non-connected party. Julian Attfield, Acting Chief Executive Officer of GeneMedix commented: "We are delighted that our restructuring efforts have begun in such a positive manner. The cash proceeds from the sale of the Chinese facility will be welcome in meeting our cash requirements in early 2006. We are also grateful to Dr Tan for his continued financial support for the Company which allows us more time to advance the current financing and corporate activities whilst continuing at full speed with our development activities." Notification of these transactions has been made today in accordance with Disclosure Rule 3.1.4R(1)(a) of the Disclosure Rules sourcebook. Following this transaction, Dr Kim Tan has a total actual beneficial interest in 128,786,159 ordinary shares, representing 34.7% of the enlarged share capital of the Company, but this will increase to a maximum of 141,858,054 ordinary shares representing 36.9% of the enlarged share capital of the Company, once the loan notes have been converted. Mr J Attfield, Acting CEO of GeneMedix, is the duly authorised officer of the Company responsible for making the notification. ENQUIRIES:
eriktherock
06/10/2005
11:05
Just read it. Don't see a problem do you?
eriktherock
06/10/2005
09:13
How about the announcement now ?
polleyn
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20161206 19:48:01